You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.
Officials from Luminex and BioNano Genomics provided strategic updates at the conference.
Sequenom CEO Bill Welch said at the JP Morgan Healthcare Conference that the company plans to bring "at least" three new laboratory-developed tests to market in 2015.
BGI's spinoff companies, BGI Tech and BGI Dx, have merged and will go public next year.
Officials from Exact Sciences, Cepheid, Bio-Rad, Biocartis, and NanoString provided strategic updates at the conference.
To date, Foundation Medicine has reported approximately 35,000 tests, of which 82 percent have a clinically relevant finding.
Officials from Thermo Fisher Scientific, Affymetrix, Danaher, Hologic, Genmark, and Accelerate Diagnostics provided strategic updates at the conference.
Officials from Genomic Health and Myriad Genetics updated investors and other attendees at the conference.
CEO Jay Flatley preannounced fourth-quarter revenues of $512 million and also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning.
NEW YORK (GenomeWeb News) – Sequenom officials on Thursday elaborated on the firm's plans to develop a lower-cost noninvasive prenatal test for fetal aneuploidy.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.